Skip to main content

Table 3 Change in primary and secondary efficacy measures from screening to week 12

From: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

 

Median score

Mean (SD) score

Median change from screening to week 12

Screening (n = 18)

Week 12 (n = 18)

Screening (n = 18)

Week 12 (n = 18)

Score (% change)

Paired-samples t test

t

Cohen’s d

Primary efficacy measures

 ADAMS

  Total

32.00

18.00

32.10 (14.36)

18.10 (8.32)

− 15.50 (− 48.90%)

− 5.74***

1.36

  Manic/hyperactive

9.00

6.00

8.80 (3.99)

6.10 (3.29)

− 2.50 (− 32.50%)

− 4.51***

1.05

  Depressed mood

2.00

1.00

2.90 (3.94)

2.00 (2.35)

0.00

− 1.54

0.37

  Social avoidance

10.00

5.00

9.90 (5.18)

4.80 (2.07)

− 5.50 (− 55.40%)

− 4.79***

1.14

  General anxiety

10.00

4.50

9.40 (4.35)

4.60 (3.35)

− 5.00 (− 52.30%)

− 7.19***

1.70

  Compulsive behavior

2.50

1.50

2.70 (2.40)

1.40 (1.42)

− 2.00 (− 57.10%)

− 2.43*

0.56

Secondary efficacy measures

 ABC-CFXS

  Social avoidance

4.50

2.50

5.10 (3.46)

2.30 (2.22)

− 3.00 (− 66.70%)

− 4.31***

1.00

  Stereotypy

8.50

2.00

8.10 (5.91)

3.20 (3.07)

− 5.00 (− 69.00%)

− 4.20***

0.99

  Socially unresponsive/lethargic

8.00

4.00

9.20 (6.40)

4.10 (4.09)

− 5.00 (− 65.20%)

− 3.40**

0.76

  Irritability

18.50

8.50

17.70 (12.68)

10.60 (11.03)

− 7.50 (− 50.00%)

− 2.92**

0.69

  Hyperactivity

10.50

8.50

13.70 (9.09)

9.80 (7.38)

− 3.50 (− 29.80%)

− 2.49*

0.59

  Inappropriate speech

6.00

3.50

5.90 (2.30)

3.50 (2.66)

− 3.00 (− 44.40%)

− 3.69**

0.87

 PARS-R

  Total severity (5-item)

14.50

9.50

15.70 (3.88)

10.60 (3.43)

− 6.00 (− 38.20%)

− 4.18***

0.98

 PedsQL

  Total score

65.20

67.80

57.80 (18.78)

67.70 (18.27)

9.80 (16.70%)

2.98*

0.77

  Physical functioning

68.80

79.70

67.90 (27.36)

78.00 (22.39)

6.30 (7.10%)

2.04

0.53

  Emotional functioning

60.00

80.00

64.00 (20.72)

78.30 (16.63)

10.00 (11.10%)

2.27*

0.58

  Social functioning

40.00

50.00

37.30 (24.70)

49.00 (24.35)

10.00 (27.80%)

1.95

0.50

  School functioning

55.00

55.00

55.70 (19.17)

59.10 (22.47)

0.00

0.95

0.25

  Psychosocial health

51.70

62.90

52.40 (17.22)

62.20 (18.91)

8.30 (16.10%)

2.25*

0.58

 VAS

  Hyperactivity/impulsivity

6.70

3.50

5.90 (2.43)

3.60 (2.49)

− 1.70 (− 44.60%)

− 4.77***

1.10

  Tantrum/mood lability

5.40

2.90

4.70 (2.09)

3.20 (2.18)

− 1.00 (− 33.90%)

− 3.59**

0.86

  Anxiety

6.50

3.80

6.00 (2.05)

3.80 (1.93)

− 2.20 (− 35.40%)

− 4.25***

1.01

 CGI

  CGI-S

5.00

5.10 (1.39)

  CGI-I

2.00

2.50 (1.01)

  1. Note. Prior to tabulation change in score at week 12 was calculated for each subject by (change = score at week 12 − score at screening), and percent change in score at week 12 was calculated for each subject by [% Change = 100 × (change at week 12/score at screening)]
  2. *p<.05 compared to screening
  3. **p<.01 compared to screening
  4. ***p<.001 compared to screening